BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oyama J, Lera-Nonose DSSL, Ramos-Milaré ÁCFH, Padilha Ferreira FB, de Freitas CF, Caetano W, Hioka N, Silveira TGV, Lonardoni MVC. Potential of Pluronics® P-123 and F-127 as nanocarriers of anti-Leishmania chemotherapy. Acta Trop 2019;192:11-21. [PMID: 30659806 DOI: 10.1016/j.actatropica.2019.01.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Brioschi MBC, Coser EM, Coelho AC, Gadelha FR, Miguel DC. Models for cytotoxicity screening of antileishmanial drugs: what has been done so far? Int J Antimicrob Agents 2022;:106612. [PMID: 35691601 DOI: 10.1016/j.ijantimicag.2022.106612] [Reference Citation Analysis]
2 Assolini JP, Carloto ACM, Bortoleti BTDS, Gonçalves MD, Tomiotto Pellissier F, Feuser PE, Cordeiro AP, Hermes de Araújo PH, Sayer C, Miranda Sapla MM, Pavanelli WR. Nanomedicine in leishmaniasis: A promising tool for diagnosis, treatment and prevention of disease - An update overview. Eur J Pharmacol 2022;923:174934. [PMID: 35367420 DOI: 10.1016/j.ejphar.2022.174934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Adeel M, Saorin G, Boccalon G, Sfriso AA, Parisi S, Moro I, Palazzolo S, Caligiuri I, Granchi C, Corona G, Cemazar M, Canzonieri V, Tuccinardi T, Rizzolio F. A carrier free delivery system of a monoacylglycerol lipase hydrophobic inhibitor. Int J Pharm 2021;613:121374. [PMID: 34906647 DOI: 10.1016/j.ijpharm.2021.121374] [Reference Citation Analysis]
4 Briones Nieva CA, Cid AG, Romero AI, García-Bustos MF, Villegas M, Bermúdez JM. An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis. Acta Trop 2021;221:105988. [PMID: 34058160 DOI: 10.1016/j.actatropica.2021.105988] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Kammona O, Tsanaktsidou E. Nanotechnology-aided diagnosis, treatment and prevention of leishmaniasis. Int J Pharm 2021;605:120761. [PMID: 34081999 DOI: 10.1016/j.ijpharm.2021.120761] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Costa AR, França RN, Silva-jardim I, Silva RJS, Lima-santos J, Salay LC, Santos RLSR. Self-assembling micellar system based on Pluronic and pyrazole-dithiocarbazate-conjugate stimulates production of nitric oxide from macrophages. Colloid and Interface Science Communications 2021;41:100378. [DOI: 10.1016/j.colcom.2021.100378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shahriyar S, Taymouri S, Saberi S, Asadi P, Tabbakhian M. Preparation and characterization of itraconazole loaded nanomicelles based on dextran-behenic acid for cutaneous leishmaniasis treatment. Drug Dev Ind Pharm 2021;47:416-28. [PMID: 33617377 DOI: 10.1080/03639045.2021.1890112] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Bakr RO, Tawfike A, El-gizawy HA, Tawfik N, Abdelmohsen UR, Abdelwahab MF, Alshareef WA, Fayez SM, El-mancy SMS, El-fishawy AM, Abdelkawy MA, Fayed MAA. The metabolomic analysis of five Mentha species: cytotoxicity, anti- Helicobacter assessment, and the development of polymeric micelles for enhancing the anti- Helicobacter activity. RSC Adv 2021;11:7318-30. [DOI: 10.1039/d0ra09334c] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Oliveira SS, Ferreira CS, Branquinha MH, Santos AL, Chaud MV, Jain S, Cardoso JC, Kovačević AB, Souto EB, Severino P. Overcoming multi‐resistant leishmania treatment by nanoencapsulation of potent antimicrobials. J Chem Technol Biotechnol 2021;96:2123-40. [DOI: 10.1002/jctb.6633] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nafari A, Cheraghipour K, Sepahvand M, Shahrokhi G, Gabal E, Mahmoudvand H. Nanoparticles: New agents toward treatment of leishmaniasis. Parasite Epidemiol Control 2020;10:e00156. [PMID: 32566773 DOI: 10.1016/j.parepi.2020.e00156] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]